Curious whether Eli Lilly’s stock is still a smart buy after its rapid rise? Let’s break down the numbers and see if the ...

Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss ...

As the biopharma world predominantly invests in late-stage assets, Eli Lilly is prioritizing early science with the opening ...

MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...

(Reuters) -Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten development cycles, getting medicines to people faster. Using the ...

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s 30-day ...

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said. The US drugmaker’s ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...

A computer-generated image of a large manufacturing facility. A computer-generated image of Eli Lilly and Company’s planned drug chemical plant in Houston Credit: Eli Lilly and Company Eli Lilly and ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus ahead of a major drug pricing deal with the Trump administration. Read more here.